Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Nectin-4 CAR-NK cells
- Development stage
- Preclinical
- Lead developer
- University of Chicago
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
Nectin-4 CAR-NK cells are an experimental adoptive cell therapy consisting of natural killer (NK) cells genetically engineered to express a chimeric antigen receptor (CAR) targeting Nectin-4 (also known as PVRL4). Nectin-4 is a cell surface adhesion molecule that is highly expressed in several malignancies, including bladder, breast, and lung cancers, while maintaining limited expression in healthy adult tissues, making it an attractive therapeutic target. These CAR-NK cells are designed to combine the innate anti-tumor surveillance of NK cells with the high-precision targeting of a CAR. Preclinical data indicates that these cells can effectively recognize and eliminate Nectin-4-positive bladder cancer cells in both 2D and 3D models, demonstrating enhanced cytotoxicity and tumor infiltration compared to unmodified NK cells.
- Other names
- Nectin-4-specific CAR-NK cellsNectin4-specific CAR-NK cellsNectin 4-specific CAR-NK cellsNectin-4-targeted CAR-NK cellsNectin4-targeted CAR-NK cellsNectin 4-targeted CAR-NK cells
02
Targets
PVRL4 (Nectin cell adhesion molecule 4)
Beyond the preview
Go deeper on Nectin-4 CAR-NK cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Nectin-4 CAR-NK cells.